Crinetics Pharmaceuticals’ Post

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can significantly impact health-related quality of life and overall well-being. As the understanding of lupus pathogenesis and management evolves, healthcare professionals have begun to explore adjunctive therapeutic strategies to complement pharmacological interventions. In recent years, there has been increasing interest in the role of physical activity and exercise as a non-pharmacological intervention to enhance the health outcomes of people living with SLE. https://lnkd.in/eDXAMF5F

Irritable Bowel Syndrome (IBS) and autoimmune diseases are distinct medical conditions that can significantly impact an individual’s quality of life. While IBS is characterized by chronic gastrointestinal symptoms, autoimmune diseases involve the immune system mistakenly attacking the body’s own cells. The intersection of these two conditions is a complex and evolving area of medical research, with emerging evidence suggesting potential links between them. https://lnkd.in/dYXpYAxe

Irritable Bowel Syndrome (IBS) and autoimmune diseases are distinct medical conditions that can significantly impact an individual’s quality of life. While IBS is characterized by chronic gastrointestinal symptoms, autoimmune diseases involve the immune system mistakenly attacking the body’s own cells. The intersection of these two conditions is a complex and evolving area of medical research, with emerging evidence suggesting potential links between them. https://lnkd.in/dYXpYAxe

I am honored to have played a small part in a study that gives new insight into the high burden of kidney disease borne by many people of African descent, including African Americans. Briefly, two variants of apolipoprotein L1 or APOL1, a component of HDL (the so-called ‘good cholesterol’), “appear to have evolved to confer protection against the African sleeping sickness parasite, Trypanosoma brucei rhodesiense” (quote from our report), some 4 to 6 thousand years ago. Those same variants, G1 and G2, put people at added risk of kidney disease, likely through damage to renal cells called podocytes. This association was already known, but the mechanism has been elusive. Here, we “establish APOL1-mediated Na+/K+ transport as the proximal driver of APOL1-mediated kidney disease.” Small-molecule drugs that modulate these transporters are under development, fostering hope for new treatments. Kudos to my colleagues, Drs. Opeyemi Olabisi and Somenath Datta, who led the charge on this study. https://lnkd.in/ejJjkzr4  

Natural anticoagulants are key regulators of hemostatic balance, and they play an important role when it comes to managing patients with hemophilia. Watch our webinar with International Society on Thrombosis and Haemostasis (ISTH) on YouTube to learn more! https://bit.ly/9247

#DYK: Green tea has protective effects against various diseases such as malignancies, cardiovascular and metabolic disorders. But recent studies have also shown that host immuno-inflammatory reactions, in addition to microbial activity, are more likely to destroy oral tissues; in such cases, green tea is considered to be a natural preventive and curative agent. https://bit.ly/4cmHqLm #GreenTea #OralHealth #InspiredByYou

🩺 It’s Rare Diseases Day! And this gives us the chance to raise awareness about this type of diseases, which happen to be more common than you might think. Most of them are lifelong, life-limiting conditions, which impact the quality of life of both the people who are affected by the disease and their caregivers; and, very often, they have no treatment options or cure.   At Novo Nordisk, we are committed to drive change through innovative treatments to improve the lives of our patients living with rare blood, endocrine and renal disorders, with a clear goal: create a better future for people living with rare disease, where they are less limited by their diagnosis and can live their life as they wish.   🤝If you want to join us in this path of improving the life of people who are living with rare diseases, check out the opportunities from this business unit on our career page: https://lnkd.in/gD-xGcHe #Rarediseasesday #drivingchange #diseaseawareness

According to the World Hypertension League (WHL), hypertension, or high blood pressure, is a major contributing factor to the global rise of non-communicable diseases (NCDs). It is considered the primary risk factor for death and disability worldwide. The WHL initiated #WorldHypertensionDay in 2005 with the objective of raising public awareness about this silent yet deadly condition, and to mobilize global efforts in combating hypertension. This year, the theme is a call to 'Measure Your Blood Pressure Accurately, Control It, Live Longer.’ #PSKAT60 #Hypertension #Pharmacology

🩺 It’s rare diseases day! And this gives us the chance to raise awareness about this type of diseases, which happen to be more common than you might think. Most of them are lifelong, life-limiting conditions, which impact the quality of life of both the people who are affected by the disease and their caregivers; and, very often, they have no treatment options or cure.   At Novo Nordisk, we are committed to drive change through innovative treatments to improve the lives of our patients living with 𝐫𝐚𝐫𝐞 𝐛𝐥𝐨𝐨𝐝, 𝐞𝐧𝐝𝐨𝐜𝐫𝐢𝐧𝐞 𝐚𝐧𝐝 𝐫𝐞𝐧𝐚𝐥 𝐝𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬, with a clear goal: create a better future for people living with rare disease, where they are less limited by their diagnosis and can live their life as they wish.   🤝If you want to join us in this path of improving the life of people who are living with rare diseases, check out the opportunities from this business unit on our career page: https://lnkd.in/grTQ5XHU           #Rarediseasesday #drivingchange #diseaseawareness

🩺 It’s rare diseases day! And this gives us the chance to raise awareness about this type of diseases, which happen to be more common than you might think. Most of them are lifelong, life-limiting conditions, which impact the quality of life of both the people who are affected by the disease and their caregivers; and, very often, they have no treatment options or cure.   At Novo Nordisk, we are committed to drive change through innovative treatments to improve the lives of our patients living with rare blood, endocrine and renal disorders, with a clear goal: create a better future for people living with rare disease, where they are less limited by their diagnosis and can live their life as they wish.   🤝If you want to join us in this path of improving the life of people who are living with rare diseases, check out the opportunities from this business unit on our career page: https://lnkd.in/e_vdzE_z           #Rarediseasesday #drivingchange #diseaseawareness